The non-genomic effects of sex hormones open the door to new therapeutic strategies and new drugs

The non-genomic effects of sex hormones open the door to new therapeutic strategies and new drugs https://i2.wp.com/www.eresviral.com/wp-content/uploads/2018/10/Los-efectos-no-genómicos-de-las-hormonas-sexuales-abren-la-puerta-a-nuevas-estrategias-terapéuticas-y-nuevos-fármacos.jpg?fit=178%2C146&ssl=1

The non-genomic effects of sex hormones open the door to new therapeutic strategies and new drugs





The non-genomic effects of sex hormones open the door to new therapeutic strategies and new drugs


The non-genomic mechanisms of the action of sex hormones in a variety of different types of human cells, including breast cancer, open new avenues of research to develop new treatments for this disease.



This research route was initiated in the 90s by a team of scientists from the University of Granada (Spain), led by Dr. Carmen Mendoza, in collaboration with the team of Dr. Jan Tesarik of the National Institute of Health and Research Medical (INSERM) French, and its results were published in the prestigious medical journal Lancet in 1997. Today, twenty years later, the idea of ​​therapeutically using the dualism of the genomic and non-genomic effects of sex hormones is materializing.



The term "sex hormones" is used for hormones that are involved in reproduction and sexuality in both sexes. The main female sex hormones are estradiol and progesterone and they are produced in the ovaries. In men, the main sex hormone is testosterone, produced by the testes. Apart from its main function, sex hormones exert a variety of effects, not related to sex, in different parts of the human body.







(Photo: MARGEN)



The mechanisms used by sex hormones to regulate the expression of specific genes in the nucleus of cells have been known for more than 50 years. These effects are called "genomic effects". However, there are also "non-genomic effects" exerted by sex hormones on the surface of cells, without entering their nucleus. In the 1990s, Doctors Mendoza and Tesarik discovered the existence of these non-genomic mechanisms of the action of sex hormones in a variety of different types of human cells, including those of breast cancer.



It is known that the loss of sex hormones contributes to the remarkable increase in the incidence of cardiovascular morbidity and mortality after menopause. The same happens in men with a low production of their main sex hormone testosterone, related or not with age. A possible hormone replacement therapy (administration of exogenous sex hormones) decreases the cardiovascular risks in these cases. However, hormone replacement may increase the risk of other diseases, especially breast cancer in women and prostate cancer in men. Two studies, one conducted by a US team and published in the Journal of Molecular and Cellular Cardiology, and another published in the journal Cardiovascular Research by researchers from the United Kingdom suggest that the preventive action of sex hormones against cardiovascular diseases would be basically mediated by the non-genomic effects, while the risks associated with the substitution treatment with these hormones is due to their genomic effects.



According to Dr. Jan Tesarik, currently director of the MARGen Clinic in Granada, "these studies mark the step towards the development of drugs that could allow hormones to exert their non-genomic effect and at the same time make their genomic effects impossible. It would be sufficient to chemically bind the sex hormones, small molecules that easily penetrate into the cells and their nuclei to exert the genomic effects, with macromolecules, such as proteins, that would prevent this passage. This would only allow these hormones to act on the surface of the target cells and exert non-genomic effects. In our work of the 1990s we used the hormones bound with the protein albumin to obtain this effect, but other types of macromolecules can be investigated, taking into account the stability, lack of toxicity and efficacy of the resulting drugs. "



The development of drugs based on sex hormones, designed to highlight their non-genomic effects, represent a scientific challenge and a hope for patients with a deficiency or total absence of the production of sex hormones, for example postmenopausal women or men with low production of sex hormones. testosterone, and with high risks of cardiovascular diseases. The suppression or modification of the genomic effects will allow to effectively treat these pathologies without raising the risk of cancer. (Source: MARGEN)

        .

  !function(f,b,e,v,n,t,s)

  {if(f.fbq)return;n=f.fbq=function(){n.callMethod?

  n.callMethod.apply(n,arguments):n.queue.push(arguments)};

  if(!f._fbq)f._fbq=n;n.push=n;n.loaded=!0;n.version='2.0';

  n.queue=[];t=b.createElement(e);t.async=!0;

  t.src=v;s=b.getElementsByTagName(e)[0];

  s.parentNode.insertBefore(t,s)}(window, document,'script',

  'https://connect.facebook.net/en_US/fbevents.js');

  fbq('init', '369524843414444');

  fbq('track', 'PageView');

    .


SOURCE LINK ERESVIRAL.COM 
https://www.beviral.online